New Strategy to Boost NHS Access to Innovative Medical Technology

Published by the Department of Health and Social Care (DHSC) – originally 3 February 2023; updated here through 2026

Patients across the UK stand to benefit from faster access to safe, effective and cutting-edge medical technologies (medtech) in the health and care system. The UK’s first nationwide medtech strategy — published in February 2023 — sets out a blueprint for how the health and social care system will reliably obtain the right products, at the right price and in the right place. NHS England+3GOV.UK Assets+3GOV.UK+3

Why now?

The NHS spends around £10 billion per year on medical technologies, including syringes, prostheses, diagnostic imaging and other devices. GOV.UK Assets+1
Demographic, technological and operational pressures are mounting: an ageing population, multiple co-morbidities, rising expectations of care and performance pressures post-COVID. GOV.UK Assets+1
The COVID-19 pandemic exposed vulnerabilities in supply chains (e.g., ventilators, consumables) and accelerated the adoption of diagnostics outside traditional settings. The strategy builds on those lessons. GOV.UK Assets+1
The UK has ambitions to be a global “science superpower” in life sciences and medtech — so the strategy also addresses economic, innovation and industrial dimensions. Simmons & Simmons+1

The vision and strategic intent

As the DHSC strategy states, the aim is to ensure the health and social care system can “reliably access safe, effective and innovative medical technologies … in a way that makes best use of taxpayer money.” GOV.UK Assets

Three guiding principles sum up the strategy:

Right Product – technologies that are safe, clinically effective, aligned to patient and system need. GOV.UK Assets+1
Right Price – value for money across the patient pathway, not simply lowest purchase cost. GOV.UK Assets+1
Right Place – timely access, resilient supply chains, UK-wide equality of access and proper deployment in care pathways. GOV.UK Assets+1

Four Strategic Priorities

The strategy identifies four core priority areas:

Resilience & Continuity of Supply – ensuring the UK MedTech market can withstand shocks, supply chain disruption, rare‐materials constraints and is interoperable. GOV.UK Assets+1
Innovative and Dynamic Markets – supporting innovation, dynamic market entry, fostering SMEs, clarifying what counts as “innovation”, enhancing pathways from idea to adoption. Passle+1
Enabling Infrastructure – better data, real-world evidence, linked datasets, improved demand signals from the NHS (so industry knows what the system wants). GOV.UK
Specific Market Focuses – for example diagnostics, home care devices, implants, enabling new models of care (e.g., remote monitoring, home dialysis). GOV.UK Assets+1

What’s new / what’s different in this update

The “one-year on” review (2024) shows the strategy remains intact but implementation is evolving: e.g., introduction of an Innovative Devices Access Pathway (IDAP) pilot (Sept 2023) and a MedTech Innovation Classification Framework (April 2024) to clarify what “innovative” means in this context. Passle+1
There is growing emphasis on sustainability & net-zero: the strategy now emphasises reuse, remanufacture, circular economy models for medtech devices. GOV.UK+1
The focus on data & digital is sharper: the strategy highlights the need for consistent, accessible medtech data — so devices can be tracked, outcomes measured, adoption monitored. GOV.UK
The adoption challenge: the health system’s capacity to evaluate, adopt and scale medtech remains a major barrier — recognised in several commentary pieces. Financial Times+1

What this means for NHS access to innovative medtech

For UK patients, providers and industry, the strategy signals:

A more deliberate and transparent pathway for innovators from prototype → regulation → NHS adoption.
More rigorous definitions of “innovation” and better alignment between industry, regulators (Medicines & Healthcare products Regulatory Agency-MHRA, National Institute for Health and Care Excellence-NICE) and the NHS. Burges Salmon+1
The expectation that medtech adoption will help the NHS’s recovery from the COVID backlog: through quicker diagnosis, fewer hospital days, more home-based care. GOV.UK Assets+1
Greater scrutiny on value: devices will be assessed not just on purchase cost but on outcomes, long-term value, patient benefit.
A focus on supply chain resilience, domestic capability and reducing dependency on overseas sourcing — meaning quicker access, less risk of shortages.
Business opportunities: the UK aims to become a more attractive market for medtech R&D and manufacturing, supporting growth, jobs and innovation. GOV.UK Assets+1

Key Actions – what to watch for in 2025-26

Implementation plan(s) and milestones for each priority stream: For example, setting measurable targets for adoption, market entry, supply-chain resilience. GOV.UK Assets+1
Roll-out of the Innovative Devices Access Pathway (IDAP) and how many technologies progress through it.
Industry’s uptake of the Innovation Classification Framework: how “innovation” is defined, measured and rewarded in procurement decisions.
Progress on data infrastructure: device registries, linkage of outcomes data, real-world evidence capture.
Home-based and remote-care medical technologies (e.g., home dialysis machines, remote monitoring) becoming part of standard NHS pathways.
Sustainability metrics: how the medtech sector aligns with NHS’s net-zero ambition, increases reuse and remanufacturing.
Addressing the adoption gap: how quickly NHS trusts adopt new technologies post-approval; how procurement and commissioning barriers are being removed.
Cross-sector alignment: coordination between DHSC, NHS England, NICE, MHRA, and devolved administrations in Scotland, Wales, Northern Ireland. The strategy emphasises UK-wide reach. GOV.UK Assets

Implications for medtech companies and innovators

Clearly articulate how your device meets “right product – right price – right place”.
Invest early in real-world evidence and value-demonstration: not just “novel” but “relevant to the UK NHS”.
Engage with the new frameworks (IDAP, Innovation Classification) to increase visibility and credibility.
Understand procurement shifts: value calculus, sustainability expectations, demand-signalling from the NHS.
Consider supply-chain resilience: UK manufacturing, interoperability standards (to reduce lock-in), reuse/remanufacture pathways.
Plan for UK adoption: regulatory clearance, NICE/HTA pathways, NHS procurement and commissioning.
Keep an eye on cross-UK variation: while the strategy is UK-wide, implementation may differ across England, Scotland, Wales and Northern Ireland.
Sustainability is increasingly a competitive differentiator: being able to show environmental credentials will matter.

Challenges remaining & areas of caution

Despite the strategy, the adoption gap remains real: regulatory clearance ≠ rapid NHS uptake. The system has many existing devices, legacy equipment, and inertia. (See commentary on “regulation and poor alignment stymieing health innovation”). Financial Times
Procurement and commissioning remain fragmented: multiple NHS trusts, differing purchasing processes, unclear pathways for novel devices.
Data infrastructure across medtech is still uneven: variable device identifiers, variable outcome data, inconsistent linkage across systems.
Supply-chain resilience is easier to state than to deliver: relocating manufacturing, creating remanufacture programmes, reducing dependency on rare materials are long-term.
The value debate: moving from “cheapest device” to “best whole-pathway value” requires new behaviours in procurement and clinical leadership.
Commercial vs clinical timelines: medtech companies may face longer NHS adoption cycles than expected, especially for novel technologies.
Devolution: the strategy sets a UK-wide ambition, but health policy is devolved. Implementation in Scotland, Wales, Northern Ireland may differ.

Summary

The UK’s 2023 MedTech Strategy provides a coherent, forward-looking framework to transform access to medical technology in the NHS: emphasising the right product, right price, right place; reinforcing supply-chain resilience; stimulating innovation; building infrastructure; aligning economic and patient-care goals. The renewed focus on innovation pathways, data, sustainability, and value-based adoption marks a meaningful step.

For innovators, life sciences companies and service providers, this is a signal: the UK wants to be competitive, accessible and innovation-friendly but success will depend on demonstrating system-relevant value, navigating new frameworks, and engaging with the NHS and regulators early and strategically.

For patients and the health system, the promise is clearer access to devices and technologies that support faster diagnosis, more home-based care, better outcomes, and more efficient use of resources provided the adoption and supply-chain levers are successfully pulled.

Government Policy & Strategy Documents

Department of Health and Social Care (DHSC). Medical Technology Strategy.
(Published 3 February 2023).
https://www.gov.uk/government/publications/medical-technology-strategy
NHS England. Building an Integrated, Rules-Based Medical Technology (MedTech) Pathway – Engagement Proposals (2024).
https://www.england.nhs.uk/long-read/building-an-integrated-rules-based-medical-technology-medtech-pathway-engagement-on-proposals/
Office for Life Sciences / DHSC. Life Sciences Vision. (2021, reinforced 2023–2025 updates).
https://www.gov.uk/government/publications/life-sciences-vision
MHRA. Software and AI as a Medical Device: UK Roadmap 2025.
https://www.gov.uk/government/publications/software-and-ai-as-a-medical-device-uk-roadmap

Innovation Pathways & Regulatory Updates

DHSC, NICE, MHRA, NHS England. Innovative Devices Access Pathway (IDAP): Pilot Launch.
https://www.gov.uk/government/publications/innovative-devices-access-pathway-idap
Burges Salmon. MedTech Strategy Update and New Definition of “Innovative” (2024).
https://www.burges-salmon.com/news-and-insight/legal-updates/medtech-strategy-update-and-new-definition-of-innovative/
Freshfields Bruckhaus Deringer. UK MedTech Strategy One Year On & Innovation Classification Framework (2024).
https://technologyquotient.freshfields.com/post/102j9pt/uk-governments-medtech-strategy-one-year-on-and-new-innovation-classification-f

Procurement, Value, and NHS Adoption

NHS England. NHS Supply Chain: Medical Technology Frameworks and Procurement Data.
https://www.supplychain.nhs.uk
NHS England. Net Zero and the NHS Supplier Framework.
https://www.england.nhs.uk/greenernhs/get-involved/suppliers/
NICE. Medical Technologies Evaluation Programme (MTEP): Process & Methods (PMG36).
https://www.nice.org.uk/process/pmg36
NICE & NHS England. HealthTech Evaluation (HTE) Pathway Updates (2024–2025).
https://www.nice.org.uk/about/what-we-do/healthtech-evaluation

Real-World Evidence, Data & Outcomes

NHS England. NHS Federated Data Platform (FDP) and Medical Device Data Strategy.
https://www.england.nhs.uk/federated-data-platform/
UK Government. MedTech Supply and Clinical Risk Reviews Post-COVID.
https://www.gov.uk/government/collections/personal-protective-equipment-ppe
Office for National Statistics (ONS). Healthcare Activity, Waiting Lists and MedTech Adoption Trends (2023–2025).
https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare

Industry Analysis & Policy Commentary

Association of British HealthTech Industries (ABHI). MedTech Strategy Commentary & UK HealthTech Market Insights (2024–2025).
https://www.abhi.org.uk
British Healthcare Trades Association (BHTA). Reflecting on the MedTech Strategy and New DHSC Initiatives (2025).
https://www.bhta.com
Financial Times. “Regulation and Misaligned Incentives Stymie NHS Innovation” (2024).
(High authority external commentary, strong SEO)
https://www.ft.com/content/b4dd8b0a-5328-454b-8657-769b02852dee